Phase ii dose. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy2

Liver Esophagogastric Junction

Organisms4

Coxiella Coxiella burnetii Rats, Sprague-Dawley Rats, Wistar

Diseases60

Neoplasms Neutropenia Nausea Thrombocytopenia Stomatitis Vomiting Lung Neoplasms Fatigue Carcinoma, Non-Small-Cell Lung Neoplasm Recurrence, Local Leukopenia Neoplasm Metastasis Disease Progression Breast Neoplasms Brain Neoplasms Hematologic Diseases Colorectal Neoplasms Peritoneal Neoplasms Ovarian Neoplasms Melanoma Kidney Neoplasms Carcinoma, Squamous Cell Biliary Tract Neoplasms Head and Neck Neoplasms Liver Neoplasms Stomach Neoplasms Recurrence Carcinoma, Renal Cell Asthenia Sarcoma Prostatic Neoplasms Diarrhea Pancreatic Neoplasms Glioblastoma Lymphoma, Non-Hodgkin Carcinoma, Small Cell Carcinoma Drug-Related Side Effects and Adverse Reactions Urologic Neoplasms Pleural Neoplasms Mesothelioma Q Fever Glioma Exanthema Radiation Injuries Anemia Bone Neoplasms Esophageal Neoplasms Anorexia Fallopian Tube Neoplasms Soft Tissue Neoplasms Rectal Neoplasms Carcinoma, Transitional Cell Brain Stem Neoplasms Neoplasms, Glandular and Epithelial Drug Eruptions Agranulocytosis Disease Models, Animal Gastrointestinal Diseases Fever

Chemicals and Drugs103

Antineoplastic Agents Paclitaxel Taxoids Camptothecin Epothilones Deoxycytidine Quinazolines Antineoplastic Agents, Phytogenic Topotecan Carboplatin Cisplatin Fluorouracil Pyrazines Antibodies, Monoclonal, Humanized Protein Kinase Inhibitors Pyridines Doxorubicin Antibodies, Monoclonal Organoplatinum Compounds Antimetabolites, Antineoplastic Vinblastine Dacarbazine Leucovorin Antineoplastic Agents, Alkylating Angiotensin II Benzenesulfonates Tegafur Phenylurea Compounds Niacinamide Etoposide Cyclophosphamide Oxonic Acid NAD(P)H Dehydrogenase (Quinone)Ifosfamide Epirubicin Drug Combinations Angiogenesis Inhibitors Thalidomide Estramustine Bridged Compounds Vincristine Antibiotics, Antineoplastic Pyrroles Granulocyte Colony-Stimulating Factor Guanine Recombinant Proteins Indoles Glutathione Transferase Pyrimidines Placebos Anthracyclines Antibodies, Monoclonal, Murine-Derived NF-E2-Related Factor 2 Depsipeptides Boronic Acids Isothiocyanates Nitrogen Mustard Compounds Benzamides Glucuronosyltransferase Glucuronides Piperazines Anticarcinogenic Agents Xenobiotics Prednisone Glutamates Platinum Compounds Thiophenes Mitoxantrone Piperidines Interferon-alpha Sulfonamides Prostate-Specific Antigen Dexamethasone Uracil Methotrexate Mesna Mitomycin Tumor Markers, Biological Pyrazoles Quinolines Dioxoles Thiocyanates Polyethylene Glycols Biomarkers, Pharmacological Plant Extracts Enzyme Inhibitors Vidarabine Phosphate Amifostine Isotretinoin Drugs, Investigational Platinum Cytarabine Receptor, Epidermal Growth Factor Iodine Radioisotopes Triazoles Prodrugs Tetrahydroisoquinolines Immunosuppressive Agents Triazines Carcinogens Melphalan Radiation-Sensitizing Agents Carmustine

Analytical, Diagnostic and Therapeutic Techniques and Equipment68

Maximum Tolerated Dose Drug Administration Schedule Infusions, Intravenous Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Area Under Curve Clinical Trials, Phase II as Topic Clinical Trials, Phase I as Topic Administration, Oral Drug Evaluation Metabolic Clearance Rate Neoplasm Staging Survival Analysis Combined Modality Therapy Survival Rate Disease-Free Survival Cohort Studies Follow-Up Studies Salvage Therapy Clinical Trials, Phase III as Topic Double-Blind Method Radiation Dosage Dose Fractionation Lethal Dose 50 Injections, Intravenous Remission Induction Kaplan-Meier Estimate Endpoint Determination Radiometry Feasibility Studies Injections, Subcutaneous Dose-Response Relationship, Radiation Prospective Studies Neoadjuvant Therapy Clinical Trials as Topic Research Design Drug Therapy, Combination Chemotherapy, Adjuvant Treatment Failure Radiotherapy Dosage Placebos Prognosis Radiotherapy Planning, Computer-Assisted Randomized Controlled Trials as Topic Chemoradiotherapy Infusions, Parenteral Radiotherapy, Adjuvant Radiotherapy, Intensity-Modulated Sample Size Administration, Intravenous Induction Chemotherapy Chromatography, High Pressure Liquid Body Burden Thermoluminescent Dosimetry Radiotherapy Patient Selection Injections, Intraperitoneal Injections, Intramuscular Disease Models, Animal Pilot Projects Probability Risk Assessment Karnofsky Performance Status Multicenter Studies as Topic Immunotherapy Radiotherapy, High-Energy Tomography, X-Ray Computed Metered Dose Inhalers

Phenomena and Processes18

Maximum Tolerated Dose Dose-Response Relationship, Drug Area Under Curve Metabolic Clearance Rate Metabolic Detoxication, Phase II Half-Life Time Factors Radiation Dosage Lethal Dose 50 Drug Resistance, Neoplasm Dose-Response Relationship, Radiation Metabolic Detoxication, Phase I Metabolic Detoxication, Drug Biological Availability Drug Interactions Biotransformation Drug Synergism Probability

Disciplines and Occupations1

Research Design

Anthropology, Education, Sociology and Social Phenomena2

Quality of Life Survival

Technology, Industry, Agriculture1

Polyethylene Glycols

Humanities1

Quality of Life

Information Science3

Survival Rate Radiotherapy Planning, Computer-Assisted Radiotherapy, Intensity-Modulated

Health Care31

Treatment Outcome Area Under Curve Clinical Trials, Phase II as Topic Clinical Trials, Phase I as Topic Survival Analysis Survival Rate Disease-Free Survival Cohort Studies Follow-Up Studies Clinical Trials, Phase III as Topic Double-Blind Method Radiation Dosage Kaplan-Meier Estimate Feasibility Studies Dose-Response Relationship, Radiation Prospective Studies Clinical Trials as Topic Treatment Failure Safety Randomized Controlled Trials as Topic Radiation Injuries Sample Size Body Burden Thermoluminescent Dosimetry Patient Selection Pilot Projects Probability Relative Biological Effectiveness Risk Assessment Karnofsky Performance Status Multicenter Studies as Topic

Publication Characteristics1

Clinical Trial, Phase II

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Health Care

Maximum Tolerated Dose Drug Administration Schedule Neoplasms Infusions, Intravenous Antineoplastic Combined Chemotherapy Protocols Dose-Response Relationship, Drug Antineoplastic Agents Treatment Outcome Area Under Curve Neutropenia Paclitaxel Clinical Trials, Phase II as Topic Taxoids Nausea Camptothecin Clinical Trials, Phase I as Topic Thrombocytopenia Epothilones Administration, Oral Drug Evaluation Deoxycytidine Quinazolines Antineoplastic Agents, Phytogenic Stomatitis Topotecan Vomiting Carboplatin Cisplatin Metabolic Clearance Rate Fluorouracil Pyrazines Lung Neoplasms Metabolic Detoxication, Phase II Antibodies, Monoclonal, Humanized Fatigue Protein Kinase Inhibitors Neoplasm Staging Pyridines Carcinoma, Non-Small-Cell Lung Doxorubicin Half-Life Time Factors Survival Analysis Combined Modality Therapy Survival Rate Disease-Free Survival Neoplasm Recurrence, Local Cohort Studies Antibodies, Monoclonal Organoplatinum Compounds Leukopenia Neoplasm Metastasis Antimetabolites, Antineoplastic Follow-Up Studies Salvage Therapy Clinical Trials, Phase III as Topic Vinblastine Disease Progression Double-Blind Method Dacarbazine Radiation Dosage Leucovorin Dose Fractionation Lethal Dose 50 Antineoplastic Agents, Alkylating Angiotensin II Injections, Intravenous Remission Induction Kaplan-Meier Estimate Benzenesulfonates Coxiella Tegafur Phenylurea Compounds Niacinamide Etoposide Breast Neoplasms Drug Resistance, Neoplasm Cyclophosphamide Endpoint Determination Oxonic Acid Brain Neoplasms NAD(P)H Dehydrogenase (Quinone)Hematologic Diseases Ifosfamide Radiometry Feasibility Studies Injections, Subcutaneous Dose-Response Relationship, Radiation Prospective Studies Colorectal Neoplasms Epirubicin Neoadjuvant Therapy Peritoneal Neoplasms Clinical Trials as Topic Research Design Ovarian Neoplasms Melanoma Drug Combinations Angiogenesis Inhibitors Kidney Neoplasms

No FAQ available that match "phase ii dose"